Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-acetylcarnosine is a synthetic derivative of the naturally occurring dipeptide carnosine. It is primarily used in ophthalmic solutions as an antioxidant to delay the progression and, in some cases, partially reverse age-related cataracts. The compound penetrates the cornea and is metabolized within the eye to L-carnosine, which protects lens proteins by scavenging free radicals, preventing cross-linking and glycation, and maintaining lens clarity. Clinical studies suggest improved visual acuity, contrast sensitivity, and delayed cataract formation after topical use. It is widely utilized as a non-surgical alternative for initial stages of cataract management and may provide protective benefits against other oxidative ocular stresses[1][2][4][5][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on n-acetylcarnosine.